Can a new injection clear psoriasis when other biologics fail?

NCT ID NCT07758075

Not yet recruiting Disease control Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This phase II trial is testing an investigational drug called SHR-1139 in adults with plaque psoriasis who have not responded well to at least one biologic treatment. Participants will receive either SHR-1139 or a placebo via subcutaneous injection over a 52-week treatment period. The main goal is to see if the drug can achieve clear or almost clear skin, measured by a score of 0 or 1 on the sPGA scale at week 16. The study also tracks improvements in psoriasis severity scores and safety over the course of the trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-1139 injection
What this could lead to: If successful, this could offer a new treatment option for people with plaque psoriasis who haven't had good results from existing biologic drugs.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not hold up in larger studies. The drug may also have side effects or not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLAQUE PSORIASIS

Contacts and locations

Locations

Xiangya Hospital of Central South University

Changsha, Hunan, 410008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.